Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy CEL-SCI Corporation stock | $14.31

Own CEL-SCI Corporation stock in just a few minutes.

Fact checked

CEL-SCI Corporation is a biotechnology business based in the US. CEL-SCI Corporation shares (CVM) are listed on the NYSE MKT and all prices are listed in US Dollars.

How to buy shares in CEL-SCI Corporation

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for CEL-SCI Corporation. Find the stock by name or ticker symbol: CVM. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until CEL-SCI Corporation reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$14.31, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of CEL-SCI Corporation, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of CEL-SCI Corporation. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

CEL-SCI Corporation share price

Use our graph to track the performance of CVM stocks over time.

CEL-SCI Corporation shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$14.31
52-week rangeUSD$7.36 - USD$18
50-day moving average USD$12.8732
200-day moving average USD$13.326
Wall St. target priceUSD$23
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.124

Buy CEL-SCI Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Forex
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Public
$0
Stocks, ETFs
N/A
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy CEL-SCI Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

CEL-SCI Corporation price performance over time

Historical closes compared with the close of $14.31 from 2020-12-09

1 week (2021-01-15) 0.28%
1 month (2020-12-23) 6.71%
3 months (2020-10-22) 4.00%
6 months (2020-07-22) 8.99%
1 year (2020-01-22) 4.15%
2 years (2019-01-22) 435.96%
3 years (2018-01-22) 550.45%
5 years (2016-01-22) 2,881.25%

CEL-SCI Corporation financials

Revenue TTM USD$606,739
Gross profit TTM USD$-12,196,533
Return on assets TTM -46.11%
Return on equity TTM -293.41%
Profit margin 0%
Book value $0.494
Market capitalisation USD$509.3 million

TTM: trailing 12 months

Shorting CEL-SCI Corporation shares

There are currently 10.2 million CEL-SCI Corporation shares held short by investors – that's known as CEL-SCI Corporation's "short interest". This figure is 1.1% down from 10.3 million last month.

There are a few different ways that this level of interest in shorting CEL-SCI Corporation shares can be evaluated.

CEL-SCI Corporation's "short interest ratio" (SIR)

CEL-SCI Corporation's "short interest ratio" (SIR) is the quantity of CEL-SCI Corporation shares currently shorted divided by the average quantity of CEL-SCI Corporation shares traded daily (recently around 558832.05689278). CEL-SCI Corporation's SIR currently stands at 18.28. In other words for every 100,000 CEL-SCI Corporation shares traded daily on the market, roughly 18280 shares are currently held short.

However CEL-SCI Corporation's short interest can also be evaluated against the total number of CEL-SCI Corporation shares, or, against the total number of tradable CEL-SCI Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CEL-SCI Corporation's short interest could be expressed as 0.26% of the outstanding shares (for every 100,000 CEL-SCI Corporation shares in existence, roughly 260 shares are currently held short) or 0.2681% of the tradable shares (for every 100,000 tradable CEL-SCI Corporation shares, roughly 268 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against CEL-SCI Corporation.

Find out more about how you can short CEL-SCI Corporation stock.

CEL-SCI Corporation share dividends

We're not expecting CEL-SCI Corporation to pay a dividend over the next 12 months.

Have CEL-SCI Corporation's shares ever split?

CEL-SCI Corporation's shares were split on a 1:25 basis on 15 June 2017. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your CEL-SCI Corporation shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for CEL-SCI Corporation shares which in turn could have impacted CEL-SCI Corporation's share price.

CEL-SCI Corporation share price volatility

Over the last 12 months, CEL-SCI Corporation's shares have ranged in value from as little as $7.36 up to $18. A popular way to gauge a stock's volatility is its "beta".

CVM.US volatility(beta: 2.2)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while CEL-SCI Corporation's is 2.1958. This would suggest that CEL-SCI Corporation's shares are significantly more volatile than the average for this exchange and represent a higher risk.

CEL-SCI Corporation overview

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site